AU2233495A - Treatment or diagnosis of abnormal signal transduction disorders - Google Patents

Treatment or diagnosis of abnormal signal transduction disorders

Info

Publication number
AU2233495A
AU2233495A AU22334/95A AU2233495A AU2233495A AU 2233495 A AU2233495 A AU 2233495A AU 22334/95 A AU22334/95 A AU 22334/95A AU 2233495 A AU2233495 A AU 2233495A AU 2233495 A AU2233495 A AU 2233495A
Authority
AU
Australia
Prior art keywords
diagnosis
treatment
signal transduction
abnormal signal
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU22334/95A
Inventor
Oliver Hobert
Bahija Jallal
Gunter Kostka
Axel Obermeier
Axel Ullrich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Original Assignee
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft zur Foerderung der Wissenschaften eV filed Critical Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Publication of AU2233495A publication Critical patent/AU2233495A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4722—G-proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
AU22334/95A 1994-03-31 1995-03-30 Treatment or diagnosis of abnormal signal transduction disorders Abandoned AU2233495A (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US221642 1980-12-31
US22164294A 1994-03-31 1994-03-31
US25169194A 1994-05-31 1994-05-31
US251691 1994-05-31
US29159194A 1994-08-15 1994-08-15
US291591 1994-08-15
PCT/US1995/003945 WO1995026983A2 (en) 1994-03-31 1995-03-30 Treatment or diagnosis of abnormal signal transduction disorders

Publications (1)

Publication Number Publication Date
AU2233495A true AU2233495A (en) 1995-10-23

Family

ID=27396973

Family Applications (1)

Application Number Title Priority Date Filing Date
AU22334/95A Abandoned AU2233495A (en) 1994-03-31 1995-03-30 Treatment or diagnosis of abnormal signal transduction disorders

Country Status (2)

Country Link
AU (1) AU2233495A (en)
WO (1) WO1995026983A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996027797A2 (en) * 1995-03-08 1996-09-12 Hsc Research And Development Limited Partnership Zap 70 inhibitors and methods for treatment of zap 70 signal transduction disorders
EP0833941B1 (en) * 1995-04-07 2008-10-22 Cytogen Corporation Polypeptides having a functional domain of interest and methods of identifying and using same
AU2002228612A1 (en) 2000-11-22 2002-06-03 Bristol-Myers Squibb Company Cloning and expression of human slap-2: a novel sh2/sh3 domain-containing human slap homologue having immune cell-specific expression
US7101686B1 (en) 2000-11-22 2006-09-05 Bristol-Myers Squibb Company Polynucleotides encoding human SLAP-2:a novel SH2/SH3 domain-containing human SLAP homologue having immune cell-specific expression
WO2002055707A2 (en) * 2001-01-10 2002-07-18 Rigel Pharmaceuticals Inc Cloning of an inhibitor of antigen-receptor signaling by a retroviral-based functional screen
WO2022251584A1 (en) * 2021-05-28 2022-12-01 St. Jude Children's Research Hospital, Inc. Methods and compositions for transduction of nk cells

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843646A (en) * 1992-02-17 1998-12-01 Howard Florey Institute Of Experimental Physiology And Medicine DNA molecules encoding murine son of sevenless (mSOS) gene and mSOS polypeptides

Also Published As

Publication number Publication date
WO1995026983A2 (en) 1995-10-12
WO1995026983A3 (en) 1996-02-08

Similar Documents

Publication Publication Date Title
AUPM864894A0 (en) Treatment of bowel-dependent neurological disorders
GB2305605B (en) Pipecolic acid derivatives for the treatment of neurological disorders
IL121170A0 (en) Compositions for the treatment of dermatological disorders
IL116998A0 (en) Novel indoline compounds processes for their preparation and their use for the treatment of CNS disorders
AU4160396A (en) Method for diagnosis of thrombotic disorders
AU6406996A (en) Compositions for the treatment and diagnosis of body weight disorders, including obesity
AUPN205095A0 (en) Diagnosis of neuromuscular dysfunction
AU2058697A (en) Treatment of sleep disorders
AU2513997A (en) Diagnosis and monitoring of neurological disease
AU1742200A (en) Prevention and treatment of amyloid-associated disorders
AU2233495A (en) Treatment or diagnosis of abnormal signal transduction disorders
GB2361872B (en) Diagnosis of medical disorders
AU4418096A (en) Diagnosis of pancreatitis
AU2187595A (en) Methods for treatment or diagnosis of diseases or conditions associated with abnormal signal transduction
AU1831195A (en) Methods and compositions for treatment and diagnosis of alzheimer disease and other disorders
AUPM456894A0 (en) Treatment for gastric disorders
AU2909495A (en) Evaluation of blood coagulation activity
AU4754496A (en) Methods for diagnosis and treatment of mdk1 signal transduction disorders
AU6460696A (en) Use of n-cyclohexyl benzamides for treating bowel disorders
AU5699396A (en) Compositions for the treatment of skin conditions
AU5430894A (en) Diagnosis of eye disorders
AU1181897A (en) Medical use of proteases
AU4670696A (en) Diagnosis of toxicoinfectious clostridiosis
AU2037800A (en) Diagnosis of human glycosylation disorders
AU4841296A (en) Diagnosis of and compositions and methods for the treatment of disease